Stay up to date with news and events
Interim update from Vico Therapeutics on their CAG-targeting drug, VO659
December 10, 2024
Vico Therapeutics recently presented at several conferences to share an interim update on their Phase 1/2a clinical trial testing their drug called VO659, which targets…
Going boldly: First person treated in Phase 1 clinical trial by Alnylam Pharmaceuticals
December 8, 2024
On December 3, 2024 we received word that the very first person received a new drug, called ALN-HTT02, as part of a Phase 1 trial…
Self-determination on the HD journey: the role of Advanced Care Planning
December 4, 2024
Here, we cover a report on Advanced Care Planning (ACP) prepared by clinical researchers at the University College London, reminding us there are things that…
Giving Thanks to the Huntington’s Disease Family Community for Advancing Research
In the spirit of gratitude, this Giving Tuesday, the HDBuzz editorial team would like to reflect on the unique and transformative role the Huntington’s disease…
2024 HDBuzz Prize: Beyond nerve cells – who are the other players in the HD brain?
November 27, 2024
A new study led by researchers from Columbia University used postmortem brain samples to show that a special type of brain cell, called astrocytes, may…